CRISPR Market worth $6.12 billion by 2031 - Exclusive Report by MarketsandMarkets
DELRAY BEACH, Fla., Oct. 16, 2026 /PRNewswire/ -- According to MarketsandMarkets, the CRISPR Market is projected to reach USD 6.12 billion by 2031 from USD 3.48 billion in 2026, at a CAGR of 12.0% during the forecast period.
Browse 388 market data Tables and 53 Figures spread through 319 Pages and in-depth TOC on "CRISPR Market - Global Forecast to 2031"
CRISPR Market Size & Forecast:
- Market Size Available for Years: 2026-2031
- 2026 Market Size: USD 3.48 billion
- 2031 Projected Market Size: USD 6.12 billion
- CAGR (2026-2031): 12.0%
CRISPR Market Trends & Insights:
- North America accounted for the largest share, 49.7%, of the CRISPR market in 2025.
- By offering, products accounted for the largest share of 70.7% of the CRISPR market in 2025.
- By application, drug discovery & development accounted for the largest share of the CRISPR market in 2025.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134401204
The CRISPR market is expanding as pharmaceutical and biotechnology companies and academic & research institutes increasingly adopt gene-editing technologies to support drug discovery, functional genomics, therapeutic development, and agricultural research. CRISPR tools are widely used for gene knockout, knock-in, target identification and validation, disease modeling, cell line development, and high-throughput screening. Rising demand for precise, efficient genome editing is accelerating adoption of CRISPR kits & enzymes, libraries, gRNA solutions, and specialized screening and validation services. In addition, ongoing advances in CRISPR-Cas systems, gRNA design and optimization, base editing, prime editing, and gene delivery technologies are improving editing specificity, efficiency, and workflow scalability. The growing development of CRISPR-based therapies and wider application of gene editing across research and commercial settings are further supporting market expansion.
By offering, the products segment held the largest share of the CRISPR market in 2025.
By offering, the CRISPR market is segmented into products and services. In 2025, products accounted for the largest market share. This is mainly due to recurring demand for CRISPR kits, enzymes, libraries, guide RNAs, and other research consumables across gene-editing workflows. Pharmaceutical and biotechnology companies, as well as academic and research institutes, use these products for gene knockout, gene activation, functional genomics, target validation, and drug discovery. The growing adoption of CRISPR-based screening and increasing gene editing research further support product consumption. Continued development of advanced Cas enzymes, optimized guide RNA solutions, and ready-to-use CRISPR kits also supports the segment's leading position.
By product type, the CRISPR kits & enzymes segment held the largest share of the CRISPR product market in 2025.
By product type, the CRISPR product market is segmented into CRISPR kits & enzymes, CRISPR libraries, and other products. In 2025, CRISPR kits & enzymes accounted for the largest market share. Their leading position is supported by their extensive use across routine gene editing, target validation, cell engineering, and functional genomics workflows. CRISPR kits provide researchers with standardized components for gene knockout, knock-in, and other genome editing experiments, while enzymes such as Cas9 and other Cas nucleases are core components of CRISPR workflows. Their broad applicability across pharmaceutical research, biotechnology R&D, and academic laboratories creates recurring demand. The availability of workflow-specific kits and improved CRISPR enzymes with enhanced editing performance further supports this segment's dominance.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=134401204
By region, North America accounted for the largest share of the market in 2025.
In 2025, North America held the largest share of the CRISPR market. This is supported by strong biotechnology and pharmaceutical research activity, high investment in gene editing, and a well-established life sciences infrastructure. The US leads the region in CRISPR-based drug discovery, functional genomics, high-throughput screening, and therapeutic development. Leading CRISPR technology providers, biotechnology companies, academic research institutes, and pharmaceutical companies create strong demand for CRISPR products and services. Growing clinical development of gene-edited therapies and continued advancements in CRISPR-Cas systems, guide RNA technologies, and screening platforms further support market growth in North America.
Key Players
Leading players in the CRISPR companies include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), GenScript (US), Takara Bio (Japan), Creative Biogene (US), Fujian SunyBiotech Co., Ltd. (China), EditCo (US), Caribou Biosciences, Inc. (US), and Lonza (Switzerland), among others.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=134401204
CRISPR Market - Investment & funding +Merger & Acquisition
Investment Funding Context
The CRISPR market is seeing increasing investment and funding activity, driven by expanding gene-editing therapeutic pipelines, advances in CRISPR-Cas technologies, and the growing development of next-generation approaches such as base editing, prime editing, and epigenetic editing. Investment activity is increasingly focused on improving editing precision and delivery, advancing therapeutic candidates through clinical development, and expanding applications across genetic diseases and other therapeutic areas. For instance, in January 2025, Tune Therapeutics raised USD 175 million in Series B financing to advance its epigenetic editing platform and therapeutic pipeline. The financing highlights continued investor interest in differentiated gene-editing technologies with potential to address a broader range of diseases. This funding activity supports technology development, clinical translation, and commercialization across the CRISPR market.
Revenue Shift Context
The CRISPR market is gradually shifting revenue from conventional CRISPR-Cas9 systems and basic gene-editing reagents toward higher-growth categories such as engineered Cas nucleases, advanced CRISPR kits, high-throughput screening solutions, base editing, prime editing, and specialized gene-editing services. The global CRISPR market is projected to increase from USD 3.48 billion in 2026 to USD 6.12 billion by 2031, at a CAGR of 12.0%, with a growing share of incremental revenues expected from advanced editing platforms, customized gRNA solutions, CRISPR libraries, cell line development, and screening & validation services. Meanwhile, conventional Cas9-based products remain an important revenue base, but next-generation editing technologies and specialized services are gaining adoption across pharmaceutical & biotechnology companies and academic & research institutes.
Mergers and Acquisitions
Mergers and acquisitions in the CRISPR market are being driven by the need to strengthen gene-editing technology portfolios, gain access to proprietary CRISPR platforms, expand therapeutic development capabilities, and acquire expertise in next-generation editing and delivery technologies. Such transactions also enable companies to broaden their presence across drug discovery, functional genomics, and CRISPR-based therapeutic development.
CRISPR MARKET: MERGERS AND ACQUISITIONS, JANUARY 2023-SEPTEMBER 2026
Month & Year | Deal Type | Company 1 | Company 2 | Description | Deal Size |
June 2025 | Acquisition | Demeetra AgBio (US) | Hera BioLabs (US) | Demeetra acquired Hera BioLabs, bringing Super piggyBac licensing, development, and commercial activities under Demeetra. The acquisition expanded Demeetra's genome-engineering portfolio and incorporated Hera's in vitro capabilities into its internal R&D operations. | NA |
July 2024 | Acquisition | Agilent Technologies, Inc. (US) | BioVectra Inc. (Canada) | Agilent Technologies, Inc. (US) acquired BioVectra, Inc. (Canada), enhancing its biopharma solutions with BioVectra's expertise in biologics and gene editing. The acquisition expanded Agilent's drug development and manufacturing capabilities. | USD 925 Million |
Company Revenue Share Details
The top four players collectively account for approximately 25-27% of the global CRISPR market, indicating a highly competitive landscape. This reflects established life sciences companies alongside specialized gene-editing technology and service providers. Key market participants include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), GenScript (US), Takara Bio (Japan), Creative Biogene (US), Fujian SunvBiotech Co., Ltd. (China), EditCo (US), Caribou Biosciences, Inc. (US), and Lonza (Switzerland). These companies compete across CRISPR kits & enzymes, libraries, gRNA solutions, cell line development, screening & validation, and other gene-editing services. Continued innovation in advanced CRISPR systems, editing optimization, high-throughput screening, and specialized services is further intensifying competition across the market.
Browse Adjacent Market: Biotechnology Market Research Reports &Consulting
See More Latest Medical Devices Reports:
Gene Editing Market by Product (Kits, Reagents, Libraries, Software), Services (gRNA Synthesis & Vector Construction), Technique (Knock-Out, Knock-In), Technology (CRISPR, ZFN, TALEN), Application (Genome Editing, Drug Discovery) - Global Forecast to 2029
Genomics Market Product (Reagents, Kits, Instruments), Services (Genome Profiling, Bioinformatics), Technology (Sequencing, PCR, ISH, Flow Cytometry), Study Type (Epigenomics), Application (Drug Discovery, Diagnostics, Agri) - Global Forecast to 2030
About MarketsandMarkets
MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts.
MarketsandMarkets SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.
To find out more, visit www.MarketsandMarkets.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/crispr-technology-market.asp
Content Source: https://www.marketsandmarkets.com/PressReleases/crispr-technology.asp
View original content to download multimedia: https://www.prnewswire.co.uk/news-releases/crispr-market-worth-6-12-billion-by-2031---exclusive-report-by-marketsandmarkets-302911142.html
